Supernus Pharmaceuticals, Inc. (SUPN)

Aristotle Capital Boston sold 503,122 shares of Supernus Pharmaceuticals in the third quarter. The move contributed to a net position change of about $10.9 million from the previous quarter....

Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript...

ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 8.8% in the undefined quarter, according to its most recen...

ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). In a filing disclosed on November 18th, the Representative disclosed that...

Bank of New York Mellon Corp raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 3.1% in the second quarter, according to its most recent 13F filing with the Securities a...

Envestnet Asset Management Inc. raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 50.2% during the undefined quarter, according to the company in its most recent Form 1...

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...

Supernus Pharmaceuticals, Inc. ( SUPN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Jack Khattar - Founder, President, CEO, Secretary & Director Timothy Dec - Senior VP & C...